T lymphocytes recognize foreign peptides in association with molecules of the major histocompatibility complex (MHC), using a diverse repertoire of T-cell receptors (TCR). These TCR are ␣␤ heterodimers generated by rearrangement of variable, diversity, and joining region gene segments during thymocyte development (58) . T-cell responses in an individual to a foreign protein from either a viral or a nonviral source is generally restricted to a few but some times only one immunodominant peptides derived by processing of the antigen (25, 61) . Various reasons have been suggested for this limitation, including availability of an appropriate peptide after antigen processing by specific intracellular proteases, specificity of peptide-MHC interactions, competition from other peptides, antagonistic activity of peptides, and limitations of the expressed T-cell repertoire (7, 20, 25) . Lymphocytic choriomengitis (LCMV), a noncytopathic RNA virus, induces in the mouse, its natural host, a protective cytotoxic T-cell (CTL) response that causes both elimination of the virus and immunopathological disease (3, 11, 14, 22, 44, 64) . The majority of LCMV-specific CD8 ϩ CTL in mice of H-2 b haplotype recognize peptides defined by residues 32 to 42 or 275 to 289 of the viral glycoprotein (GP) (CTL epitope [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] (24, 34, 47, 55) . These represent 50 to 60%, 10 to 20%, and 20 to 30% of the total CTL activity, respectively.
There is evidence indicating that noncytopathic or poorly cytopathic viruses may mutate epitopes recognized by CTL and thereby escape CTL recognition and control (for reviews, see references 36 and 41) . Infection with virus variants with particular changes in the peptide sequences defining immunodominant determinants may therefore modify the virus-host relationships in an MHC-dependent fashion. We evaluated this issue by defining distinct CTL epitope mutants of LCMV-WE and studying the CD8 ϩ CTL response in C57BL/6 mice infected with these variants. The results of this study reveal limitations in the plasticity of an antiviral CTL immune response. They suggest that infection with virus variants that are resistant to specific CTL or emergency of such variants in situ may modulate the immune response to viruses, facilitating a prolonged persistence of the infectious agent and possibly leading to chronic immunopathological disease in the host.
MATERIALS AND METHODS

Animals. C57BL/6 (H-2 b
) and BALB/c (H-2 d ) mice were obtained from the Institut für Zuchthygiene (University of Zurich, Switzerland).
Cells and culture conditions. The generation, maintenance, and specificity of the CTL clones 50.1 and B23.35 (B23), which are specific for the T-cell epitope defined by residues 275 to 289 of the LCMV GP [LCMV-GP-(275-289)] have been described in detail elsewhere (2, 6, 52) . The ␣␤ TCR clone was established from a C57BL/6 mouse carrying the transgenic TCR ␣ and ␤ chains specific for the LCMV-GP-(32-42) (53). Polyclonal CTL specific for the T-cell epitope defined by residues 32 to 42 or 275 to 289 of the LCMV GP or for residues 397 to 407 of the LCMV NP were obtained by restimulation of memory spleen cells from virus-infected C57BL/6 mice with macrophages loaded with the corresponding peptides (Neosystem Laboratories, Strasbourg, France). Primary antiviral splenic CTL were prepared as single-cell suspensions from animals infected intravenously (i.v.) with 100 PFU of the LCMV wild-type strain WE or the variant isolates. Cells used as target cells were MC57G (H-2
Selection of virus variants.
The WE strain of LCMV was originally obtained by F. Lehmann-Grube (Hamburg, Germany). Stock virus was grown on L929 cells from a triple-purified virus. Virus titers were determined on L929 cell monolayer cultures (38) or with an immunological focus assay (8) . The generation and characterization of LCMV-8.7, a variant obtained from LCMV-specific TCR-transgenic mice infected with 10 6 PFU of LCMV-WE, has been described previously (55) . LCMV-WE variants CL1.2 and 8.7-B23 were selected in vitro by using a procedure described previously (1). Briefly, MC57G or B6-SV40 cells (3 ϫ 10 5 cells per well) were seeded into six-well tissue culture plates and infected with LCMV at multiplicities of infection of 1 to 0.01, CTL (2 ϫ 10 6 to 3 ϫ 10 6 ) were added 1 to 4 h later, and the supernatants containing virus were collected after 48 h, titrated, and tested in a standard cytotoxicity assay. Virus isolates were cloned twice or three times by plaque purification as described previously (56) . LCMV-CL1.2 was isolated from cell cultures infected with LCMV-WE in the presence of polyclonal CTL specifically recognizing the CTL epitope defined by residues 275 to 289 of the LCMV GP. The 8.7-B23 variant of LCMV-WE was obtained by infecting cells in vitro with LCMV-8.7 together with the CTL clone B23, which recognizes the CTL epitope defined by residues 275 to 289 of the LCMV GP (52) .
Detection of antiviral CTL activity in the spleen of mice infected with LCMV-WE or virus variants. The frequencies of antiviral CTL precursor cells (CTLp) were determined under limiting-dilution conditions as described in detail previously (43) . The antiviral CTL activities were determined in a standard 51 Cr release assay for 4 to 5 h. MC57G cells were infected with LCMV-WE of its variants at multiplicities of infection of 0.001 to 0.2 for 2 days or were loaded with peptides for 2 h. The peptide of LCMV-WE or variants defined by residues 32 to 42 (IKAVYNFATCG or IKALYNFATCG) or 275 to 289 (SSGVENPGGY CLTKW, SSGVEDPGGYCLTKW, or SSGVESPGGYCLTKW) of the LCMV GP or residues 397 to 407 (QPQNGQFIHFY) of the LCMV NP (Neosystem Laboratories) were used at 100 M for coating of the target cells. Effector cells were clones or polyclonal CTL specific for particular viral CTL epitopes. The primary CTL activity in the spleens of virus-infected mice was expressed as lytic units per spleen; a lytic unit was defined as the number of splenocytes required to lyse one-third of a standard number of target cells (10 4 cell per well) (46) . Quantification of infectious virus in tissues of infected mice. The quantification of infectious virus in the spleen and kidney of mice infected with a low (10 2 PFU i.v.) or high (10 7 PFU i.v.) does of LCMV-WE or of variants has been described previously (38) .
Sequence analysis of LCMV-WE variants. LCMV-WE selectants (8.7, CL1.2, and 8.7-B23) were purified from cell culture supernatants by using procedures described previously (49) . Viral RNA was isolated by digestion with proteinase K, phenol-chloroform extraction, and sequential precipitation with ethanol. Viral RNA (2 g) was then used as a template for DNA synthesis by reverse transcriptase (Moloney murine leukemia virus; Pharmacia Uppsala, Sweden), using the manufacturer's conditions and the following specific primers: I (5Ј-TCG TAGCATTGTCACAGAATTCTTC-3Ј), complementary to nucleotides 1014 to 1037 of the viral S-RNA and amplifying the region including the CTL epitope defined by residues 32 to 42 and 275 to 289 of the LCMV GP; II (5Ј-GAGAG GCCTCAAGCTTCTGGAAGT-3Ј), complementary to nucleotide 2945 to 2967 of the viral S-RNA and amplifying the region of the viral nucleoprotein including the CTL epitope defined by residues 397 to 407; and III (5Ј-GATCCGAAGTC TACATCAAAG-3Ј), complementary to nucleotides 3061 to 3081 of the viral S-RNA and amplifying the region of the LCMV NP including the CTL epitope defined by residues 118 to 132.
The cDNA was amplified by PCR using Taq polymerase (Boehringer, Mannheim, Germany) with primers I and IV (5Ј-GAATTCTATCCAGTAAAAG GATGG-3Ј; complementary to nucleotides 58 to 81 of the viral S-RNA), with primers II and V (5Ј-GGGAGAGCACCTATAACTGATGAGG-3Ј; complementary to nucleotides 1976 to 2000 of the viral S-RNA), or with primers III and VI (5Ј-CCCTTACTACACCACTTGC-3Ј; complementary to nucleotides 2841 to 2859 of the viral S-RNA). PCR was run for 42 cycles on a thermal cycler (Perkin-Elmer Cetus Corp., Emeryville, Calif.). Denaturation was for 1 min at 94ЊC, and extension for 3 min at 72ЊC. The PCR product was isolated from the agarose gel by using a Millipore filter (QTY UF OHV25 ultrafree MC; 0.45-mm pore size; Pharmacia, Uppsala, Sweden) and sequenced with a Taq dye-deoxyterminator cycle sequencing kit on an Applied Biosystem 373A DNA sequencing system (Foster City, Calif.) according to the manufacturer's conditions. To avoid PCR artifacts, viral RNA was sequenced from at least four independent virus preparations. In addition, both strands were sequenced by using suitable primers. Sequences were compared to those for WE described previously (57) . The LCMV-WE variants were analyzed further in a cytotoxicity assay, using as effector cells either clones or polyclonal CTL specific for particular epitopes of LCMV-WE (Fig. 2) . The 8.7 and 8.7-B23 variants were not recognized by the ␣␤ TCR-transgenic CTL clone, and polyclonal CTL specific for epitope 32-42 of LCMV-WE showed greatly (Ͼ10 times) reduced cytotoxicity. The recognition of epitope 275-289 of variants CL1.2 and 8.7-B23 by specific CTL was completely abolished. Target cells (MC57G) infected with these variants were as susceptible as LCMV-WE-infected target cells to lysis by CTL specific for the respective unchanged epitopes. In addition, polyclonal CTL from BALB/c mice (H-2 d ) specifically recognized epitope 118-132 and efficiently lysed D2 target cells infected with LCMV-WE or its variants (data not shown). Further experiments were performed to evaluate whether LCMV-WE variants were able to induce CTL specific for their variant peptides. For this purpose, splenocytes from C57BL/6 mice infected i.v. with 100 PFU of the variants of WE were tested on day 8 to 10, periods of maximum CTL activity, using MC57G target cells infected with virus or labelled with peptides of the CTL epitopes of LCMV-WE or of variants. The data confirmed the absence of CTL activities specific for the variant peptides of CL1.2 and 8.7-B23 at CTL epitope 275-289 and considerably reduced activity for the peptide of 8.7 variant at epitope 32-42 (Table 1 and data not shown). These observations were extended in experiments using CTL obtained by restimulation several times in vitro with variant peptides of splenocytes from C57BL/6 mice infected with the mutants; CTL activities specific for variant peptide 275-289 of CL1.2 or 8.7-B23 were not detectable. The peptide of 8.7 induced CTL which recognized and lysed target cells labelled with variant peptide 32-42 or infected with 8.7 virus efficiently as has been reported previously (54) (37) . LCMV-WE variants induced distinct levels of antiviral CTL activity in C57BL/6 mice (Fig. 3) . The double mutant 8.7-B23 induced a considerably lower level of overall antiviral CTL activity compared with the variants with one altered CTL epitope or wild-type WE. This correlated with reduced cytotoxicity for CTL epitope 32-42 and absence of specific activity for epitope 275-289. CL1.2 and 8.7 variants induced comparable levels of CTL activity despite the absence or reduced 3) . The ability of C57BL/6 mice to eliminate CTL-resistant variants from different tissues was tested in mice infected i.v. with a relatively low dose (10 2 PFU) or high dose (10 7 PFU) of the virus. Virus titers were determined in the spleen and kidney during a period of 100 days after the infection (Fig. 4B) . At low doses, the viruses were eliminated within a period of 2 weeks. It is noteworthy that higher (about 100 times) virus titers were detected on day 5 after infection in the kidneys of mice infected with a low dose of double-mutated virus than in kidneys of mice infected with other variants or WE. Infection with 10 7 PFU caused persistence of the 8.7-B23 variant in the tested tissues for up to 100 days. Elimination of variants 8.7 and CL1.2 variants was complete by day 20 except for variant 8.7 in kidneys. The capacity of C57BL/6 mice to eliminate LCMV has been correlated in an earlier study with the relative frequencies of antiviral CTLp (46) . The levels of antiviral CTLp during induction and during the memory phase were therefore determined in the mice infected with 10 7 PFU (or 10 2 PFU; data not shown) of LCMV-WE or the variants (Fig. 4A) . The frequencies of antiviral CTLp induced after infection with CL1.2 did not differ from those of mice infected with the wild-type WE. Infection with 8.7 initially led to extensive expansion of CTLp (days 6 to 10); they rapidly declined to a low level around day 20 and later increased again to a level comparable to that observed on day 10 of infection. In general, the CTLp memory levels induced by 8.7 were three-to fivefold lower than those found after infection with WE. In contrast, a long-lasting profound reduction of CTLp was observed in mice infected with 8.7-B23 up to day 100; the frequencies of CTLp were about 50-fold lower than those after infection LCMV-WE. The profound transient reduction of CTLp on day 20 after infection with the 8.7 or 8.7-B23 variant is reminiscent of the exhaustion of antiviral CTLp after infection with LCMV-Docile or C1 13-Armstrong (46) . This reduction was absent in mice infected with a low dose of 10 2 PFU i.v. (data not shown). Inoculation i.c. of a relatively low dose of 10 2 PFU of LCMV usually induces a characteristic lethal LCM, mediated preferentially by antiviral CTL (6, 14, 27) . Inoculation of a relatively high dose (Ͼ10 6 PFU) has been shown to protect mice sometimes from lethal LCM (high-dose immune paralysis) (30, 50) . To assess the role of variations within viral CTL epitopes in the development of disease mediated by antiviral CTL, we tested the LCMV-WE variants for the ability to cause high-dose immune paralysis. LCMV-WE or CL1.2 virus injected i.c. at 10 6 or 10 7 PFU per mouse spared about 75% of inoculated C57BL/6 mice. In contrast, 8.7 virus failed to cause lethal LCM when injected i.c. at 10 5 PFU per mouse. The LCMV-8.7-B23 variant caused high-dose immune paralysis most readily; a relatively low dose of 10 3 to 10 4 PFU i.c., but not higher doses, was lethal for about 50% of the infected mice. The effect of the CTL epitope mutations on susceptibility of LCM was specifi- ) mice with the variants or WE wild-type virus revealed comparable susceptibilities to LCM (Fig. 5) .
RESULTS
Characterization of LCMV variants exhibiting
DISCUSSION
This report provides evidence that CTL escape variant viruses that have mutated one to two but not all three CTL epitopes reduce the overall CTL response and therefore may facilitate persistence of the noncytopathic virus in the host; thus, even partial CTL escape of noncytopathic viruses may change the virus-host relationships and severity of immunopathological disease significantly. LCMV variants which escape from recognition by antiviral CTL have been defined by mutations within the amino acid sequence of the immunodominant CTL epitope in mice of the MHC H-2 b haplotype. The relevant escape mechanisms occur as a result of alterations in anchor residues affecting peptide binding (mutation within epitope, 275-289 of CL1.2 and 8.7-B23 virus) or in non-anchor residues affecting recognition (mutation within epitope 32-42 of 8.7 or 8.7-B23). In the first case, the change in the anchor position (N3D in CL1.2 or N3S in 8.7-B23) prevents binding by D b and therefore also recognition by T cells. In the latter case, the variant peptide binds to D b and K b MHC molecules and will be recognized by variant peptide-specific CTL restricted preferentially to K b molecules, but overall it does not induce a pronounced CTL response to that epitope in vivo.
Whether this reflects similarity to a self-peptide, defect in the TCR repertoire, or another mechanism remains unclear. As tested so far in vitro, the 8.7 peptide does not act as a competitor for the corresponding wild-type WE peptide (3a) and does not block expression of MHC class I.
Accumulation of mutations in various CTL epitopes in the noncytopathic LCMV gradually changes the antiviral CTL response of the host. Infection with variants possessing alterations in one of the three H-2 b -restricted CTL epitopes did not impair CTL responses considerably. The excess of antiviral CTL activity directed to unchanged epitopes enabled recovery from the viral infection. In contrast, infection with a variant carrying substitutions within two of three CTL epitopes modified its host relationship significantly. This variant replicated widely in different tissues of the mouse and induced a reduced CTL response; this resulted in persistent viral infection and prevented immunological disease in the host. These results suggest several questions. Why can mutations in two but not all CTL epitopes have such a significant effect on the virus-host relationship? What is the survival advantage of such variants in the infected host? To what extent may CTL escape variants, either preexisting in the infectious inoculum or emerging in situ, contribute to create conditions which permit viral persistence? Can such variants spread though a population of individuals differing in MHC type?
The finding that mutated virus with mutations in two major CTL epitopes on GP but possessing an unaltered third epitope in NP suggests that changes that may be considered to be relatively small influence the biological equilibrium between virus and host immune system significantly. This does not come as too much of a surprise, since relatively subtle differences between LCMV isolates in susceptibility to alpha, beta, or gamma interferon, in replication kinetics, or in tropism, in addition to several other host factors, including H-2 (4, 45, 48) , influence the host-virus equilibrium significantly.
Recent investigations have provided some insights into how relative immunodominance in the class I-restricted CTL responses may be explained. Although the affinity of MHC class I-peptide binding clearly has a role in selecting determinants recognized by CTL, proteolytic mechanisms involved in processing of antigen, peptide stability, peptide transport, and the CTL repertoire may also account for immunodominance (7, 13, 21, 42, 59) . The limited available data, however, cannot yet explain the hierarchical distribution of antiviral CTL reactivities in H-2 b mice, postulating differences in affinities of peptide-MHC H-2D b or -K b interactions. In addition to these discussed factors, clonal deletion by exhaustion may be enhanced by CTL escape mutations and change overall kinetics of both virus and CTL responses to prevent lethal immunopathology, which is the parameter used as a main readout in this study.
Unfortunately, a precise quantification is not yet possible for most of these parameters.
To avoid recognition by the host's CTL response, viruses use various mechanisms such as (i) antigen mimicry (viral peptides presented by class I MHC molecules may mimic self-peptides) (12) . (ii) variations in MHC molecules that alter presentation of particular CTL epitopes (17, 18, 41) , (iii) viral interference with T-cell recognition by down-regulation of MHC class I expression or of proteins that alter or block presentation of viral peptides by MHC class I molecules (28, 40) , and finally (iv) selection of CTL-resistant variants. The latter case would seem to be a precarious situation in protective immunity to infectious pathogens that frequently mutate and change antigens. Variations in the sequence of the viral genome may affect CTL recognition by different ways: by blocking correct transport and processing of the antigen, blocking binding to MHC (9, 10) . In the latter two examples, not only T-cell epitope escape mutants but also antagonostic viruses that exhibit epitopes that seem to be able to anergize CTL of the original specificity have been found (10, 35) . It is noteworthy that CTL escape mutants have been described for viruses that are genetically unstable and that tend to persist in the host. It would not be to the selective advantage of a rapidly lethal, lytic virus to emphasize this mechanism. These studies collectively reveal that mutations within the viral genome causes them to evade recognition by CTL through a variety of mechanisms and suggest that the cumulative action of various escape variants may modulate the virus-host relationship toward persistence of a noncytopathic virus. The clear impact of H-2 on susceptibility to LCM in general, as shown earlier (4, 48, 50) , and of sequence variations affecting H-2 b -restricted CTL activities on the virus-host relationships and phenotype of disease illustrates that the relative number of available CTLp is rather limited in the host and has a direct influence on these parameters. This has also been demonstrated in a comparative study infecting BALB/c (H-2 d ) and BALB/c H-2 dm2 mutant mice with LCMV-Docile or C1 13-Armstrong. The BALB/c H-2 dm2 mice are not able to present the CTL epitope defined by residues 118 to 132 of the LCMV NP because of lack of presenting L d MHC molecules and consequently mount a weak response specific for the LCMV GP (references 4, 26, and 29), and unpublished observations). Virus clearance was drastically impaired in the mutant mice, and the susceptibility to CTL exhaustion was vastly increased (4, 45, 63) .
What are the consequences of the shift in relative CTL kinetics caused by elimination of one or two of three relevant CTL epitopes? As has been point out before and clearly documented here, such mutations could be relevant only for a host of a particular MHC class I configuration. Somewhat surprisingly, the data from this report suggest the probability that even partial CTL escape may have significant effects on the virus-host relationship. Because the CTL response during a viral infection is usually polyclonal and polyspecific, this renders emergence of variants, predominating within the replicating virus, difficult but not impossible. Infection with variants lacking one or more immunodominant epitopes may create the condition for further selection of CTL escape mutants in the infected host. Furthermore, accumulation of variants with an array of mutations affecting several CTL epitopes may represent reservoirs of highly virulent viruses for a broad population of individuals across several MHC haplotypes. Although direct evidence for the implication of CTL escape mutants with respect to mechanisms of viral persistence in the broad context of viral epidemiology are rare and indirect, there are interesting examples that have recently come to light; first, mutations in epitopes of the human immunodeficiency virus protein Gag, which are presented by HLA-B8, have been found and are not recognized by CTL present in the same patient (51); second, loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from A11-positive populations by selective mutations of anchor residues has been reported (17) ; third, selection of CTL escape variants in a subset of patients with chronic hepatitis B virus infection who express a narrow repertoire of anti-hepatitis B virus CTL has been suggested to contribute to viral persistence (9) . Therefore, it is possible that during the course of infection with noncytopathic viruses, variant viruses that become increasingly less recognizable by CTL in hosts of differing MHC class I types may emerge and thereby change the subtle virus-host relationships and disease patterns.
